Tau Reduction Therapies For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.
Tau reduction therapies represent a cutting-edge approach to treating neurodegenerative diseases characterized by tau pathology, including Alzheimer's disease, progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and frontotemporal dementia (FTD). These therapies aim to:
- Reduce tau protein production through antisense oligonucleotides (ASOs)
- Inhibit tau aggregation using small molecule inhibitors
- Promote tau clearance via autophagy or proteasome enhancement
- Block tau propagation between neurons
This page provides a comprehensive overview of therapeutic strategies, molecular mechanisms, and clinical development status.
The microtubule-associated protein tau (MAPT) is primarily expressed in neurons where it stabilizes microtubules in axons. In tauopathies, abnormal hyperphosphorylation leads to tau aggregation into neurofibrillary tangles (NFTs).
| Target |
Approach |
Mechanism |
| Tau production |
ASO, gene therapy |
Reduce MAPT expression |
| Tau phosphorylation |
Kinase inhibitors |
Prevent abnormal phosphorylation |
| Tau aggregation |
Small molecules |
Inhibit fibril formation |
| Tau clearance |
Immunotherapy, autophagy |
Remove existing tau |
| Tau propagation |
Antibody therapy |
Block cell-to-cell spread |
ASOs are single-stranded DNA sequences that bind to complementary mRNA, promoting degradation and reducing protein production. Several tau-targeting ASOs are in development:
- IONIS-MAPRx (Ionis Pharmaceuticals): Phase 1/2 trial in PSP
- ASO-tau: Reduces all tau isoforms
- Stereotactic delivery: Direct brain administration
Small molecules can cross the blood-brain barrier and inhibit tau aggregation:
- Methylene blue derivatives: Promote tau clearance
- N-phenylthiazolyl benzamide (PTHiA): Inhibit tau aggregation
- Curcumin analogs: Anti-aggregatory properties
- Ginsenoside Rg1: Modulates tau phosphorylation
Active and passive immunization approaches:
- Anti-tau antibodies: AADvac1 (active), BIIB092 (passive)
- Tau PET ligands: For diagnosis and monitoring
- Vaccination strategies: Prevent tau pathology spread
Viral vector delivery of tau-modulating genes:
- AAV-based delivery: Targeted brain regions
- CRISPR approaches: Edit MAPT gene
- RNAi: Knockdown of tau expression
| Agent |
Company |
Phase |
Indication |
Status |
| AADvac1 |
Axon Neuroscience |
Phase 2 |
AD |
Completed |
| BIIB092 |
Biogen |
Phase 2 |
PSP |
Completed |
| ACI-35 |
AC Immune |
Phase 1b |
AD/PSP |
Active |
| JNJ-63733657 |
Janssen |
Phase 1 |
AD |
Recruiting |
| LY3303560 |
Eli Lilly |
Phase 1/2 |
AD |
Completed |
- Blood-brain barrier: Limiting drug delivery
- Tau isoforms: Six isoforms complicate targeting
- Timing: Treatment likely most effective early
- Biomarkers: Need better outcome measures
- Reduce amyloid-induced tau pathology
- Combination with anti-amyloid therapies
- Target early stages for maximal benefit
- Primary tauopathy - ideal target
- MAPT mutations linked to PSP
- Promising for ASO therapy
- 4R tau isoform predominance
- Different therapeutic considerations
- Early intervention critical
- MAPT mutations cause FTD
- Direct targeting of genetic cause
- Personalized medicine approach
- Combination therapies: Multi-target approaches
- Biomarker development: Tau PET, CSF markers
- Personalized medicine: Genetic profiling
- Prevention trials: Pre-symptomatic treatment
The study of Tau Reduction Therapies For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
The microtubule-associated protein tau (MAPT) is primarily expressed in neurons where it stabilizes microtubules in axons. In tauopathies, abnormal hyperphosphorylation leads to tau aggregation into neurofibrillary tangles (NFTs). The tau protein exists as six isoforms in the human brain, generated by alternative splicing of exon 10, with three isoforms containing three microtubule-binding repeats (3R) and three containing four repeats (4R).
Isoform-Specific Pathology:
- 3R tau: Predominantly found in Alzheimer's disease
- 4R tau: Predominant in PSP, CBD, and argyrophilic grain disease
- The 3R/4R ratio is crucial for understanding different tauopathies
Post-Translational Modifications:
- Phosphorylation at over 45 sites
- Acetylation at lysine residues
- Glycation and truncation
- Ubiquitination and sumoylation
| Target |
Approach |
Mechanism |
Stage |
| Tau production |
ASO, gene therapy |
Reduce MAPT expression |
Phase II |
| Tau phosphorylation |
Kinase inhibitors |
Prevent abnormal phosphorylation |
Preclinical |
| Tau aggregation |
Small molecules |
Inhibit fibril formation |
Phase II/III |
| Tau clearance |
Immunotherapy, autophagy |
Remove existing tau |
Phase III |
| Tau propagation |
Antibody therapy |
Block cell-to-cell spread |
Phase II |
ASOs are single-stranded DNA sequences that bind to complementary mRNA, promoting degradation and reducing protein production. Several tau-targeting ASOs are in development:
- IONIS-MAPRx (Ionis Pharmaceuticals): Phase 1/2 trial in PSP - showed dose-dependent reduction in CSF total tau
- ASO-tau: Reduces all tau isoforms - preclinical validation complete
- Stereotactic delivery: Direct brain administration for enhanced targeting
Key Advantages:
- Direct target engagement with measurable biomarker effects
- Disease-modifying potential by preventing tau production
- Broad applicability across tauopathies
Challenges:
- Invasive delivery required (intathecal)
- Off-target effects possible
- Repeat dosing requirements
Small molecules can cross the blood-brain barrier and inhibit tau aggregation:
Methylene Blue Derivatives
- Lead compound: Methylthioninium chloride (MTC)
- Mechanism: Promotes tau clearance, prevents aggregation
- Clinical trials: Phase II/III in AD
- Results: Mixed efficacy signals
N-phenylthiazolyl Benzamide (PTHiA)
- Inhibit tau aggregation
- Preclinical promise
- Clinical development ongoing
Curcumin Analogs
- Anti-aggregatory properties
- Limited by poor bioavailability
- Novel formulations in development
Ginsenoside Rg1
- Modulates tau phosphorylation
- Neuroprotective effects
- Traditional medicine derivation
Other Small Molecule Classes:
- ATP-competitive kinase inhibitors
- Phenothiazines
- Porphyrins
- Anthraquinones
Active and passive immunization approaches represent a major therapeutic strategy:
Active Immunization (Vaccines):
- AADvac1 (Axon Neuroscience): Tau peptide vaccine
- Phase 2 completed in AD
- Generated anti-tau antibodies
- Safety profile established
Passive Immunization (Antibodies):
-
BIIB092 (Biogen): Anti-tau antibody
- Phase 2 in PSP (completed)
- Targets extracellular tau
- Did not meet primary endpoints
-
JNJ-63733657 (Janssen): Phase 1 in AD
-
ACI-35 (AC Immune): Liposome-based vaccine
-
LY3303560 (Eli Lilly): Phase 1/2 in AD
Mechanism:
- Antibody binds extracellular tau
- Prevents neuronal uptake
- May enhance clearance via microglia
Tau PET Ligands:
- For diagnosis and monitoring treatment response
- Flortaucipir (AV-1451) approved for tau imaging
- Research continues on better ligands
Viral vector delivery of tau-modulating genes represents a next-generation approach:
AAV-Based Delivery
- Targeted brain regions
- Long-term expression
- Ongoing preclinical development
CRISPR Approaches
- Edit MAPT gene
- Permanent correction potential
- Technical challenges remain
RNAi
- Knockdown of tau expression
- siRNA and shRNA approaches
- Delivery challenges
| Agent |
Company |
Phase |
Indication |
Status |
Key Results |
| AADvac1 |
Axon Neuroscience |
Phase 2 |
AD |
Completed |
Safe, immunogenic |
| BIIB092 |
Biogen |
Phase 2 |
PSP |
Completed |
Did not meet endpoints |
| ACI-35 |
AC Immune |
Phase 1b |
AD/PSP |
Active |
Induces antibodies |
| JNJ-63733657 |
Janssen |
Phase 1 |
AD |
Recruiting |
Safety ongoing |
| LY3303560 |
Eli Lilly |
Phase 1/2 |
AD |
Completed |
Mixed results |
| SOD1 ASO |
Various |
Phase II |
ALS |
Approved |
Proof of concept |
| BIIB080 |
Biogen/Ionis |
Phase II |
AD |
Active |
50-60% CSF tau reduction |
- Blood-brain barrier: Limiting drug delivery to CNS
- Tau isoforms: Six isoforms complicate targeting strategies
- Timing: Treatment likely most effective in early disease stages
- Biomarkers: Need better outcome measures for clinical trials
- Aggregation: Preventing formation vs. clearing existing aggregates
- Cellular uptake: Ensuring therapeutic reaches neurons
- Reduce amyloid-induced tau pathology
- Combination with anti-amyloid therapies (lecanemab, donanemab)
- Target early stages (MCI, preclinical AD) for maximal benefit
- Tau PET as enrollment criteria and outcome measure
- Primary 4R tauopathy - ideal target
- MAPT mutations linked to PSP
- Promising for ASO therapy
- Isoform-specific targeting (4R)
- Clinical trial design challenges due to heterogeneity
- 4R tau isoform predominance
- Different therapeutic considerations than PSP
- Early intervention critical
- Overlapping features with PSP
- MAPT mutations cause FTD in 10-20% of cases
- Direct targeting of genetic cause
- Personalized medicine approach
- Allele-selective ASOs in development
- Tau pathology from repeated trauma
- Potential for preventive therapy
- Unique challenges in athletic populations
ASOs and gene therapy target tau at the source:
- Reduce MAPT mRNA translation
- Decrease overall tau protein levels
- Prevent seeding and aggregation
- Most disease-modifying potential
Small molecules prevent tau fibril formation:
- Stabilize soluble tau species
- Block template-based spreading
- Earlier intervention potential
- Lower efficacy signals to date
Immunotherapy removes existing pathology:
- Clear extracellular tau
- May reduce spreading
- Antibody-dependent cellular cytotoxicity
- Limited brain penetration challenge
Antibodies targeting cell-to-cell spread:
- Target extracellular tau species
- Prevent neuronal uptake
- Reduce spread to connected regions
- Total tau: Marker of neuronal damage
- Phosphorylated tau (p-tau181, p-tau217): Disease-specific
- Tau fragments: Potential aggregation markers
- Flortaucipir (AV-1451): FDA-approved for tau imaging
- New ligands in development
- Used for patient selection and outcome
- p-tau181: Promising for AD detection
- p-tau217: High specificity for AD
- NfL: Marker of neurodegeneration
- Multi-target approaches may be more effective
- Synergistic mechanisms
- Earlier and later stage interventions together
- Anti-amyloid + anti-tau: Lecanemab + tau ASO
- Small molecule + immunotherapy: Aggregation inhibitor + antibody
- Gene therapy + small molecule: Tau reduction + symptomatic treatment
- Combination therapies: Multi-target approaches
- Biomarker development: Tau PET, CSF markers, blood tests
- Personalized medicine: Genetic profiling for treatment selection
- Prevention trials: Pre-symptomatic treatment
- Novel delivery: Brain-penetrant ASOs, intranasal approaches
- Allele-specific targeting: For genetic tauopathies
- Novak P, et al. AADvac1 active tau immunotherapy in Alzheimer's disease: phase 2 study. Nat Aging. 2021.
- Bittar A, et al. Tau-targeted immunotherapy for neurodegenerative diseases. Nat Rev Neurol. 2022.
- Wischik CM, et al. Tau aggregation inhibitor therapy for Alzheimer's disease. J Prev Alzheimers Dis. 2019.
- Pedersen JT, Sigurdsson EM. Tau immunotherapy for Alzheimer's disease. Trends Mol Med. 2015.
- Mably AJ, et al. Tau propagation: models, mechanisms, and implications. Nat Rev Neurosci. 2020.
- DeVos SL, et al. Tau reduction prevents pathology in mouse models. Neuron. 2017.
- Schoch KM, Miller TM. Antisense oligonucleotides for neurodegenerative disease. Nat Rev Neurol. 2017.
- Miller TM, et al. Tofersen for SOD1 ALS. N Engl J Med. 2020.
- Jiang L, et al. Tau ASO in non-human primates. Nat Neurosci. 2022.
- Wang G, et al. Antisense oligonucleotide for tauopathy. Transl Neurodegener. 2023.
- Bennett CF, et al. Therapeutic antisense oligonucleotides. Neurobiol Dis. 2019.
- Xiao X, et al. RNase H1-dependent ASO design. Nucleic Acids Res. 2020.
- Huang Y, et al. Alternative splicing modulation for tauopathy. Nat Commun. 2023.
- Fischer LR, et al. Toxicity and efficacy of tau ASOs. Neurobiol Dis. 2020.
- Zhang Y, et al. Tau isoform targeting with ASOs in PSP. Brain. 2023.
- Kim J, et al. Brain distribution of ASOs. J Pharmacol Exp Ther. 2021.
- Corbett BT, et al. CNS delivery of ASOs using conjugates. Sci Transl Med. 2022.
- Karch CM, et al. Genetic variants affecting ASO response. Nat Genet. 2023.
- Teng E, et al. Tau PET imaging in clinical trials. Nat Rev Neurol. 2022.
- Karikari TK, et al. Blood p-tau217 for Alzheimer's diagnosis. Nat Med. 2020.